J. Kahwaji

发表

Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization

A. Sinha, M. Haas, S. Jordan, 2015, Transplantation.

Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab

S. Jordan, J. Mirocha, N. Reinsmoen, 2013, Transplantation.

Advances in diagnosing and managing antibody-mediated rejection

S. Jordan, N. Reinsmoen, A. Vo, 2010, Pediatric Nephrology.

Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients

M. Haas, D. Dragun, S. Jordan, 2010, Transplantation.

Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.

M. Haas, S. Jordan, J. Mirocha, 2017, Kidney international.

IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation

C. Nast, M. Haas, K. Wood, 2017, The New England journal of medicine.

A Phase I/II Trial of the Interleukin-6 Receptor–Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients

M. Haas, S. Jordan, N. Reinsmoen, 2015, Transplantation.

Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab

M. Haas, S. Jordan, A. Vo, 2014, Clinical transplantation.

B-cell immunotherapeutics: emerging roles in solid organ transplantation

S. Jordan, A. Vo, M. Toyoda, 2011, Current opinion in organ transplantation.

Risk factors associated with the development of histocompatibility leukocyte antigen sensitization

S. Jordan, A. Vo, Irene K Kim, 2016, Current opinion in organ transplantation.

Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients

S. Jordan, J. Mirocha, B. Shin, 2017, Journal of immunology research.

Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

S. Jordan, N. Reinsmoen, A. Vo, 2010, Transplantation.

COVID-19 in solid organ transplant: A multi-center cohort study

M. Ison, A. Limaye, W. Bennett, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen‐sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab

J. Mirocha, S. Ge, A. Vo, 2015, Transplant infectious disease : an official journal of the Transplantation Society.

Rituximab: An emerging therapeutic agent for kidney transplantation

S. Jordan, A. Vo, C. Tong, 2009 .

Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab.

N. Chai, S. Jordan, J. Mirocha, 2011, Transplant immunology.

A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients

M. Haas, S. Jordan, N. Reinsmoen, 2015, Transplantation.

ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation?

S. Jordan, A. Vo, J. Kahwaji, 2010, Expert review of clinical immunology.

Six‐year outcomes in broadly HLA‐sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab

S. Jordan, A. Vo, Jua Choi, 2016, Transplant international : official journal of the European Society for Organ Transplantation.

Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients

M. Haas, S. Jordan, N. Reinsmoen, 2014, Transplantation.

Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.

S. Jordan, N. Reinsmoen, A. Vo, 2012, Transplantation proceedings.

Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.

A. Sinha, S. Jordan, N. Reinsmoen, 2011, Clinical journal of the American Society of Nephrology : CJASN.

[Neuro-Behçet in a Sub-Saharan Africa Country: a Series of Sixteen Patients in Fann Teaching Hospital, Dakar, Senegal].

M. Thioub, M. Mbaye, A. Sow, 2019, Bulletin de la Societe de pathologie exotique.

Assessment of Tocilizumab (Anti–Interleukin‐6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody‐Mediated Rejection and Transplant Glomerulopathy in HLA‐Sensitized Renal Allograft Recipients

M. Haas, A. Loupy, S. Jordan, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Modern approaches to incompatible kidney transplantation.

S. Jordan, Stanley C Jordan, A. Vo, 2015, World journal of nephrology.

Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection

C. Nast, S. Jordan, Hao Zhang, 2017, Transplantation.

Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.

S. Jordan, E. Klapper, A. Vo, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients

A. Vo, M. Toyoda, S. Jordan, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Efficacy, Outcomes, and Cost-Effectiveness of Desensitization Using IVIG and Rituximab

J. Petrozzino, A. Sinha, S. Jordan, 2013, Transplantation.

Viral‐specific cytotoxic T‐cell responses in HLA‐sensitized kidney transplant patients maintained on everolimus and low‐dose tacrolimus

S. Jordan, Ruan Zhang, S. Ge, 2022, Transplant infectious disease : an official journal of the Transplantation Society.

Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.

S. Jordan, A. Vo, J. Kahwaji, 2016, Transplantation proceedings.

Clinical Outcomes of Kidney Transplant Recipients Switched to Belatacept Based Regimen.: Abstract# A199

S. Jordan, A. Vo, Jua Choi, 2014 .

Cause of Death With Graft Function Among Renal Transplant Recipients in an Integrated Healthcare System

J. Hsu, S. Bunnapradist, J. Kahwaji, 2011, Transplantation.

Progress in Desensitization of the Highly HLA Sensitized Patient.

S. Jordan, A. Vo, Jua Choi, 2016, Transplantation proceedings.

Belatacept Conversion Protocols and Outcomes in Kidney Transplant Recipients.

J. Kahwaji, S. Meguerditchian, Roland Lee, 2021, Transplantation proceedings.

How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients?

J. Kahwaji, Ryszard R Dudek, 2006, The Permanente journal.

Intravenous Immunoglobulin (IVIG) a Modulator of Immunity and Inflammation with Applications in Solid Organ Transplantation

S. Jordan, A. Vo, M. Toyoda, 2012 .

Overview of renal transplantation.

S. Hashmi, S. Bunnapradist, J. Kahwaji, 2007, Minerva Medica.

Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.

A. Sinha, S. Jordan, N. Reinsmoen, 2011, Clinical journal of the American Society of Nephrology : CJASN.